Biohaven Pharmaceutical Holding Price to Sales Ratio 2016-2022 | BHVN
Historical PS ratio values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current P/S ratio for Biohaven Pharmaceutical Holding as of May 27, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Biohaven Pharmaceutical Holding P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-05-27 |
143.37 |
|
13.06 |
| 2022-03-31 |
118.57 |
$10.97 |
10.80 |
| 2021-12-31 |
137.81 |
$7.15 |
19.28 |
| 2021-09-30 |
138.91 |
$4.81 |
28.90 |
| 2021-06-30 |
97.08 |
$3.03 |
32.07 |
| 2021-03-31 |
68.35 |
$1.77 |
38.72 |
| 2020-12-31 |
85.71 |
$1.08 |
79.41 |
| 2020-09-30 |
65.01 |
$0.48 |
135.02 |
| 2020-06-30 |
73.11 |
$0.19 |
394.13 |
| 2020-03-31 |
34.03 |
$0.02 |
1667.85 |
| 2019-12-31 |
54.44 |
0 |
0.00 |
| 2019-09-30 |
41.72 |
0 |
0.00 |
| 2019-06-30 |
43.79 |
0 |
0.00 |
| 2019-03-31 |
51.47 |
0 |
0.00 |
| 2018-12-31 |
36.98 |
0 |
0.00 |
| 2018-09-30 |
37.55 |
0 |
0.00 |
| 2018-06-30 |
39.52 |
0 |
0.00 |
| 2018-03-31 |
25.76 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.111B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
